Hypertension

High blood pressure increases a patient's risk of heart attack, stroke and other diseases. Most people with hypertension have no symptoms. The Centers for Disease Control and Prevention (CDC) says nearly half of U.S. adults have hypertension, or high blood pressure, and only about 1 in 4 of those individuals has their hypertension under control. The World Health Organization (WHO) expects the epidemic of hypertension world-wide will exceed 1.56 billion people by 2025. Major efforts are underway to better control this primary risk factor through screenings, medication and invasive procedures such as renal denervation in severely uncontrolled patients.

RSS icon
Deepak Bhatt, MD, discusses the long-term, positive SYMPLICITY HTN-3 trial results presented at TCT 2022, and the future of renal denervation therapy to treat hypertension. #TCT

VIDEO: SYMPLICITY HTN-3 and the future of renal denervation

Deepak Bhatt, MD, MPH, details long-term outcomes from the SYMPLICITY HTN-3 trial, which show a lasting impact on patients with uncontrolled hypertension. 

Thumbnail

How the COVID-19 pandemic has impacted blood pressure management in the US

A new analysis of more than 137,000 patients found that the early months of the pandemic were associated with some concerning trends for hypertension patients. 

Thumbnail

FDA announces new recall of blood pressure medication due to potential cancer risk

Patients impacted by this recall are advised to speak with a physician about how to proceed. 

FDA recall. The medications involved are atenolol, which treats hypertension, and clopidogrel, which reduces the risk of an acute myocardial infarction (AMI) or stroke among patients with a history of AMI, severe chest pain or circulation problems.

FDA announces recall of 2 cardiovascular medications due to labeling mix-up

Patients face a risk of adverse events if they mistakenly take the wrong medication, according to a new warning from the FDA. 

The Pulnovo pulmonary artery denervation catheter. In February 2021, the devices was granted the U.S. Food and Drug Administration (FDA) breakthrough device designation. #TCT2022 #PAH

Pulmonary artery denervation shows promise to treat pulmonary arterial hypertension

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

Thumbnail

Cardiologists sound the alarm as ‘staggering’ new data suggest CVD rates in the U.S. will rise dramatically

New data from the CDC and U.S. Census Bureau show just how bad CVD rates could get in the next few decades. Specialists agree that a lot of work is needed to help keep these estimates from becoming a reality. 

High blood pressure more than doubles risk of COVID-19 hospitalization

Adults that received three doses of an mRNA COVID vaccine were 2.6 times as likely to be hospitalized if they also had high blood pressure. 

RAAS inhibitors lower risk of aneurysm rupture among patients with high blood pressure

Researchers also noted that uncontrolled hypertension, exposure to second-hand smoke and untreated type 2 diabetes were all associated with a greater rupture risk.

Displaying 41 - 48 of 83
Design by Adaptive Theme